Health Care·Pharmaceuticals·$276.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.85 | N/A | +11.84% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.85 | N/A | +11.84% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding the company's earnings performance. However, they did not provide specific guidance for future quarters.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing investments in research and development as a key focus.
This earnings report indicates that Merck & Co. Inc. performed better than expected in terms of earnings per share. However, the lack of revenue figures and guidance leaves some uncertainty about future performance. The stock reaction is not available, making it difficult to assess immediate investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WASTE CONNECTIONS IN
Apr 27, 2015